Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
From the article
You might also wanna read
Experimental drug apitegromab aims to prevent muscle loss from weight-loss injections
Apitegromab, a new drug currently in clinical trials, is being developed to prevent muscle loss (often called 'Ozempic butt') caused by GLP-
bbc.co.uk·1mo ago
Wegovy's Canadian Launch and AI's Role in Accelerating Weight Drug Discovery
The article discusses the shifting metabolic health landscape, highlighting obesity as a complex disease and the launch of Wegovy in Canada
startuphub.ai·8d ago
Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption
This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica
bmj.com·19d ago
AI Analysis of Reddit Posts Identifies Potential Side Effects of GLP-1 Weight Loss Drugs
Researchers at the University of Pennsylvania used AI to analyze over 410,000 Reddit posts spanning six years to identify potential side eff
sciencealert.com·1mo ago
GLP-1 Therapy Reduces Migraine Frequency by More Than Half in Obesity Patients
A study from the University of Naples found that liraglutide, a GLP-1 receptor agonist typically used for diabetes and obesity, significantl
medlink.com·7mo ago
Two Observational Studies Link GLP-1 Receptor Agonists to Reduced Breast Cancer Risk in Women with Obesity
Two observational studies found that GLP-1 receptor agonists (like Ozempic, Wegovy) are associated with reduced breast cancer incidence in w
mdsc.pe·13d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.